EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Will centralized drug procurement policy improve enterprises’ total factor productivity?

Xin Li, Ran Tao, Wenxue Zou, Yuning Jin

Frontiers in Public Health · 2025

DOI: 10.3389/fpubh.2025.1504342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, 2025. Verfasst von Xin Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Capital University of Economics and Business, Beijing, China. Hauptthemen laut MEDLINE: Drug Industry, Efficiency, Organizational, Health Policy, Drug Costs. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Against the backdrop of China’s healthcare reform challenges in drug pricing, this study investigates the impact of the National Centralized Drug Procurement (NCDP) policy implemented in 2018. Employing Difference-in-Differences (DID) methodology on quarterly data from A-share listed pharmaceutical firms (2003-2021, sourced from WIND/CSMAR databases), we demonstrate that NCDP participation significantly reduces Total Factor Productivity . Robustness is confirmed through index substitution, propensity score matching, and lag tests. The negative effect is amplified in non-state-owned enterprises, non-TCM manufacturers, and firms with high analyst coverage. Mechanistically, NCDP suppresses TFP through: (i) tightened financing constraints (↑KZ index) impairing capital allocation efficiency, and (ii) an indirect pathway where short-term R&D surges (↑RD) trigger resource crowding-out effects, compounded by diminished investment efficiency (↑INV), ultimately forming an “R&D→investment inefficiency→TFP↓” transmission chain. To reconcile public welfare objectives with corporate sustainability, we propose dual optimization strategies: differentiated financing support and innovation incentive reform . These establish a sustainable equilibrium between price control and TFP enhancement, providing actionable solutions for nationwide NCDP scaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryEfficiency, OrganizationalHealth PolicyDrug CostsHumansChina

Stichwörter der Autor:innen

financing constraintshealthcare policy reformlisted drug manufacturing enterprisesnational centralized drug procurementtotal factor productivity

Autor:innen und Institutionen

  • Capital University of Economics and Business, Beijing, China.
  • Financial Interbank Department, Beijing Rural Commercial Bank, Beijing, China.

Zitieren

APA

Li, X., Tao, R., Zou, W., & Jin, Y. (2025). Will centralized drug procurement policy improve enterprises’ total factor productivity?. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1504342

Vancouver

Li X, Tao R, Zou W, Jin Y. Will centralized drug procurement policy improve enterprises’ total factor productivity?. Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1504342

BibTeX
@article{Li2025,
  author = {Li, Xin and Tao, Ran and Zou, Wenxue and Jin, Yuning},
  title = {Will centralized drug procurement policy improve enterprises’ total factor productivity?},
  journal = {Frontiers in Public Health},
  year = {2025},
  doi = {10.3389/fpubh.2025.1504342}
}
Kostenlos starten →